Venöz Malformasyonlar ve Kliniği
Synopsis
Venöz malformasyonlar (VM'ler), vasküler anomaliler içinde en yaygın görülen yavaş akımlı vasküler malformasyonlardır. Bu malformasyonlar, venöz pleksusun gelişimindeki konjenital anormalilerden kaynaklanır ve bunun sonucunda hipertrofik ve nonfonksiyonel damarların oluşmasına yol açar. VM'lerin çoğu genellikle doğumda mevcuttur. Semptomlar, malformasyonların konumlarına ve invazyon derecelerine bağlı olarak değişkenlik gösterir ve yaşam kalitesini etkileyebilir. VM'lerin patogenezi genetik ve kalıtsal faktörlere dayanmaktadır. Çoğu VM, TEK veya PIK3CA gibi belirli genlerde oluşan mutasyonlarla ilişkilidir. Bu mutasyonlar, damarların gelişimini etkileyerek VM'lerin oluşumuna sebep olur. Sinyal yollarındaki anormallikler de VM'lerin patogenezinde rol oynamaktadır. VM'lerin tanısı genellikle klinik muayene ve görüntüleme teknikleri ile konulmaktadır. Doppler ultrasonografi ve manyetik rezonans görüntüleme (MRG), VM'lerin değerlendirilmesinde en yaygın olarak kullanılan yöntemlerdendir. Laboratuvar testleri ve nadiren biyopsi de tanı sürecine katkıda bulunabilir. VM'lerin yönetimi multidisipliner bir yaklaşım gerektirir ve tedavi planlaması hastanın semptomlarına, malformasyonun konumuna ve yaygınlığına bağlı olarak değişkenlik gösterir. Cerrahi rezeksiyon ve skleroterapi, VM'lerin tedavisinde yaygın olarak kullanılan yöntemlerdir. Destekleyici tedaviler arasında elastik kompresyon ve ağrı kontrolü de bulunur. Ancak, tedavi yöntemlerinin etkinliği hakkında net kanıtlar bulunmamakla beraber, tedavi yönetim yaklaşımı genellikle hastanın özel durumuna ve klinisyenin deneyime dayanır. VM'lerin belirli klinik varyantları, örneğin kutano-mukozal venöz malformasyonlar veya glomovenöz malformasyonlar, özel tanı ve yönetim gerektirebilen durumlardandır. Sonuç olarak, VM'ler nadir görülen ancak önemli sağlık sorunlarına yol açabilen vasküler anomalilerdir. Tanı ve tedavide multidisipliner yaklaşım gereklidir ve tedavi seçenekleri hastanın durumuna bağlı olarak belirlenir.
Venous malformations (VMs) are the most common slow-flow vascular malformations among vascular anomalies. These malformations result from congenital abnormalities in the development of the venous plexus, resulting in hypertrophic and nonfunctional veins. Most VMs are usually present at birth. Symptoms vary depending on the location and degree of invasion of the malformations and may affect quality of life. The pathogenesis of VMs is based on genetic and hereditary factors. Most VMs are associated with mutations in specific genes such as TEK or PIK3CA. These mutations affect the development of blood vessels, leading to the formation of VMs. Abnormalities in signalling pathways also play a role in the pathogenesis of VMs. VMs are usually diagnosed by clinical examination and imaging techniques. Doppler ultrasonography and magnetic resonance imaging (MRI) are the most commonly used methods in the evaluation of VMs. Laboratory tests and rarely biopsy may also contribute to the diagnostic process. Management of VMs requires a multidisciplinary approach and treatment planning varies depending on the patient's symptoms, location and extent of the malformation. Surgical resection and sclerotherapy are commonly used methods in the treatment of VMs. Supportive therapies include elastic compression and pain control. However, there is no clear evidence on the efficacy of treatment modalities, and the management approach is usually based on the patient's specific condition and the experience of the clinician. Certain clinical variants of VMs, such as cutaneous-mucosal venous malformations or glomovenous malformations, may require specialised diagnosis and management. In conclusion, VMs are rare vascular anomalies that can lead to significant health problems. A multidisciplinary approach is required in diagnosis and treatment, and treatment options are determined depending on the patient's condition.
References
Nguyen HL, Bonadurer GF, 3rd, Tollefson MM. Vascular Malformations and Health-Related Quality of Life: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018;154(6):661-9.
Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet. 2007;16 Spec No. 2:R140-9.
Soblet J, Kangas J, Nätynki M, Mendola A, Helaers R, Uebelhoer M, et al. Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations. J Invest Dermatol. 2017;137(1):207-16.
Vikkula M, Boon LM, Carraway KL, 3rd, Calvert JT, Diamonti AJ, Goumnerov B, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87(7):1181-90.
Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2009;41(1):118-24.
Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, et al. Somatic Activating PIK3CA Mutations Cause Venous Malformation. Am J Hum Genet. 2015;97(6):914-21.
Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94(4):455-9.
Amyere M, Aerts V, Brouillard P, McIntyre BA, Duhoux FP, Wassef M, et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet. 2013;92(2):188-96.
Brouillard P, Boon LM, Mulliken JB, Enjolras O, Ghassibé M, Warman ML, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet. 2002;70(4):866-74.
Boon LM, Mulliken JB, Enjolras O, Vikkula M. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol. 2004;140(8):971-6.
Revencu N, Vikkula M. Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet. 2006;43(9):716-21.
Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43(12):1256-61.
Uebelhoer M, Nätynki M, Kangas J, Mendola A, Nguyen HL, Soblet J, et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet. 2013;22(17):3438-48.
Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004;118(2):149-61.
Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171-80.
Boscolo E, Limaye N, Huang L, Kang KT, Soblet J, Uebelhoer M, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest. 2015;125(9):3491-504.
Si Y, Huang J, Li X, Fu Y, Xu R, Du Y, et al. AKT/FOXO1 axis links cross-talking of endothelial cell and pericyte in TIE2-mutated venous malformations. Cell Commun Signal. 2020;18(1):139.
Mazoyer E, Enjolras O, Bisdorff A, Perdu J, Wassef M, Drouet L. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol. 2008;144(7):861-7.
Behravesh S, Yakes W, Gupta N, Naidu S, Chong BW, Khademhosseini A, et al. Venous malformations: clinical diagnosis and treatment. Cardiovasc Diagn Ther. 2016;6(6):557-69.
Casanova D, Boon LM, Vikkula M. [Venous malformations: clinical characteristics and differential diagnosis]. Ann Chir Plast Esthet. 2006;51(4-5):373-87.
Dompmartin A, Acher A, Thibon P, Tourbach S, Hermans C, Deneys V, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol. 2008;144(7):873-7.
Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology. 2010;25(5):224-35.
Dubois J, Soulez G, Oliva VL, Berthiaume MJ, Lapierre C, Therasse E. Soft-tissue venous malformations in adult patients: imaging and therapeutic issues. Radiographics. 2001;21(6):1519-31.
Goyal M, Causer PA, Armstrong D. Venous vascular malformations in pediatric patients: comparison of results of alcohol sclerotherapy with proposed MR imaging classification. Radiology. 2002;223(3):639-44.
Enjolras O. Classification and management of the various superficial vascular anomalies: hemangiomas and vascular malformations. J Dermatol. 1997;24(11):701-10.
Dompmartin A, Baselga E, Boon LM, Diociaiuti A, Dvorakova V, El Hachem M, et al. The VASCERN-VASCA Working Group Diagnostic and Management Pathways for Venous Malformations. J Vasc Anom (Phila). 2023;4(2):e064.
van der Vleuten CJ, Kater A, Wijnen MH, Schultze Kool LJ, Rovers MM. Effectiveness of sclerotherapy, surgery, and laser therapy in patients with venous malformations: a systematic review. Cardiovasc Intervent Radiol. 2014;37(4):977-89.
Dompmartin A, Ballieux F, Thibon P, Lequerrec A, Hermans C, Clapuyt P, et al. Elevated D-dimer level in the differential diagnosis of venous malformations. Arch Dermatol. 2009;145(11):1239-44.
Boon LM, Vanwijck R. [Medical and surgical treatment of venous malformations]. Ann Chir Plast Esthet. 2006;51(4-5):403-11.
